BEAT Share Price Performance
US$1.18
-0.65 (-35.52%)
76.8% undervalued intrinsic discount
US$5.08
Fair Value
Price US$1.18
AnalystConsensusTarget US$5.08
AnalystLowTarget US$4.00
AnalystHighTarget US$8.00
Fair ValueUS$5.08
Share Pricen/a
HeartBeam, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
BEAT Community Narratives
AN
Fair Value US$5.08 76.8% undervalued intrinsic discount
Concierge Cardiac Care And AI Collaboration Will Shape A Long Term Bullish View
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$4 70.5% undervalued intrinsic discount
Home Cardiac Diagnostics And AI Delays Will Restrain Progress Yet Eventually Support Potential Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$8 85.3% undervalued intrinsic discount
At Home ECG Clearances And AI Pipeline Will Transform Cardiac Care Over Time
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Concierge Cardiac Care And AI Collaboration Will Shape A Long Term Bullish View
Catalysts About HeartBeam HeartBeam develops portable, cable free 12 lead ECG technology for at home and ambulatory cardiac assessment. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$5.08
76.8% undervalued intrinsic discount
Fair Value
Profit Margin
13.08%
Future PE
106.27x
Price in 2029
US$0
At Home ECG Clearances And AI Pipeline Will Transform Cardiac Care Over Time
Catalysts About HeartBeam HeartBeam develops portable, cable free ECG technology that lets patients capture clinical grade 12 lead readings at home or on demand. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$8
85.3% undervalued intrinsic discount
Fair Value
Profit Margin
13.36%
Future PE
109.7x
Price in 2029
US$0
Home Cardiac Diagnostics And AI Delays Will Restrain Progress Yet Eventually Support Potential Upside
Catalysts About HeartBeam HeartBeam develops a portable, cable free ECG system intended to give patients at home clinical grade 12 lead readings supported by remote cardiologist review. What are the underlying business or industry changes driving this perspective?Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$4
70.5% undervalued intrinsic discount
Fair Value
Profit Margin
12.57%
Future PE
72.21x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Concierge Cardiac Care And AI Collaboration Will Shape A Long Term Bullish View
Fair Value: US$5.08 76.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
At Home ECG Clearances And AI Pipeline Will Transform Cardiac Care Over Time
Fair Value: US$8 85.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Home Cardiac Diagnostics And AI Delays Will Restrain Progress Yet Eventually Support Potential Upside
Fair Value: US$4 70.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
HeartBeam, Inc. Key Details
About BEAT
- Founded
- 2015
- Employees
- 16
- CEO
- WebsiteView website
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart’s electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician portal, and powerful cloud-based algorithms. HeartBeam, Inc. was incorporated in 2015 and is based in Santa Clara, California.
Recent BEAT News & Updates
